MECP2 POLYMORPHISMS IN SLE

$228,082P20FY2010RRNIH

Oklahoma Medical Research Foundation, Oklahoma City OK

Investigators

Linked publications, trials & patents

Paper 38389303 Paper 37645944 Paper 31453437 Paper 31199565 Paper 26783109 Paper 26713507 Paper 26512198 Paper 26385092 Paper 25865496 Paper 25338677 Paper 25205108 Paper 25180293 Paper 24871463 Paper 24702955 Paper 24598797 Paper 24267974 Paper 24267917 Paper 24227780 Paper 24187561 Paper 23977035 Paper 23950893 Paper 23884468 Paper 23874208 Paper 23740754 Paper 23637325 Paper 23468661 Paper 23441136 Paper 23112091 Paper 23096411 Paper 22952805 Paper 22917660 Paper 22904263 Paper 22833143 Paper 22753952 Paper 22696686 Paper 22523428 Paper 22505704 Paper 22504579 Paper 22488302 Paper 22464253 Paper 22231568 Paper 22203994 Paper 22189356 Paper 22187488 Paper 22184503 Paper 22174698 Paper 22166114 Paper 22166002 Paper 22160803 Paper 22155868 Paper 22110124 Paper 22088620 Paper 22001415 Paper 21978998 Paper 21952918 Paper 21918955 Paper 21900951 Paper 21868574 Paper 21840425 Paper 21792837 Paper 21765104 Paper 21719445 Paper 21715372 Paper 21686066 Paper 21637784 Paper 21614020 Paper 21590681 Paper 21532063 Paper 21441445 Paper 21437871 Paper 21436623 Paper 21425124 Paper 21408207 Paper 21401576 Paper 21379322 Paper 21336280 Paper 21270825 Paper 21162028 Paper 21077276 Paper 20971583 Paper 20881011 Paper 20848568 Paper 20847738 Paper 20844739 Paper 20706608 Paper 20662065 Paper 20498198 Paper 20485490 Paper 20484116 Paper 20396862 Paper 20224770 Paper 20215141 Paper 20191587 Paper 20178135 Paper 20112382 Paper 19939855 Paper 19880499 Paper 19877080 Paper 19851445 Paper 19762402

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this study, resequencing will be used to further characterize the MECP2 gene in individuals with the risk and protective haplotypes, searching for novel variants. These variants will then be assayed in an independent series of cases and controls. Additionally, chromatin immunoprecipitation will be used to determine the affects of these variants on DNA/protein complexes.

View original record on NIH RePORTER →